Eli Lilly And Co vs Nerdwallet Inc — how do they compare? Eli Lilly And Co trades at $1,220.94 (market cap $1.08T), while Nerdwallet Inc trades at $9.55 (market cap $625.17M). The key difference: Eli Lilly And Co is far larger — about 1727.5× Nerdwallet Inc's market cap, and Eli Lilly And Co pays a 0.57% dividend while Nerdwallet Inc pays none. Which is the better fit depends on your goals.
| LLY | NRDS | |
|---|---|---|
Market Cap | $1.08T | $625.17M |
Sector | Health | Financials |
52-Week High | $1.24K | $15.93 |
52-Week Low | $639.43 | $7.58 |
Enterprise Value | $1.13T | $539.47M |
Dividend Yield | 0.57% | — |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.
LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.
NerdWallet (NRDS) trades at $9.48, down 3.27% today, amid mixed signals. The stock shows bullish technical momentum with a 10.87 P/E ratio indicating potential undervaluation. Revenue grew to $836.6M in 2025, with net income reaching $48.7M, though Q2 2026 earnings missed expectations. Positive analyst sentiment includes a 66.66% buy rating, with news highlighting a 27.9% upside potential from Zacks Investment Research on August 10, 2026.
Outlook is cautiously optimistic with strong profitability margins and cash flow growth, but risks include organic-search pressure and competitive threats. The stock's valuation and recent momentum suggest upside, though investors must monitor earnings consistency and market volatility.
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →